Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (2621)	1/7/2019 3:32:37 PM
From: Miljenko Zuanic	Respond to of 3559

The Qs were focused over Eylea/Dupi market dynamic (Eylea PD expansion, CMS part B effects, Dupi-asthma penetration/AD-expansion,..answered with confidence and with common sense....), while on pipeline front Qs were on IO, rule of CD3 and new bispecific platform (CD28). While CD3 and CD28 are relative new (uncertain, and Sanofi bailed out leaving REGN with "holding the bag"....did they already forgot Eylea (aflibercept) arrangement and failure on their part????..), I think that Sanofi priorities are not on IO/IO. They fear BMS/MRK have significant lead and investment may over-burn potential return. Contrary, REGN feels opposite...time will tell who is right. Anyway, I would suggest Conference present. and Q&A parts, make own notes on Qs and project where they stand. Their burn rate will increase , 19/20, profit will shrink, but few years from now (IF anyone have patience to hold that long) pay-off may be there??? I surely hope it will, but...who hold "crystal-boll"???? Cheers!